GlassScriptPhysician profile
Barbara Maria Celeiro
NPI 1346200797
$1,848.79
in general payments reported to CMS, 2019-2025
19 companies · $584 in 2025
The $584 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.57 · 2022: $250 · 2023: $603 · 2024: $383 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $230.46 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $189.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $152.55 | 2024-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $133.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.13 | 2022-2025 | Farxiga, Airsupra |
| Idorsia Pharmaceuticals US INC | $60.65 | 2022-2023 | Quviviq |
| Abbott Laboratories | $42.82 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $38.60 | 2024 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $35.55 | 2023 | Qutenza |
| Phadia US INC. | $32.37 | 2023-2024 | Immunocap |
| Vanda Pharmaceuticals INC. | $32.28 | 2022 | |
| Inspire Medical Systems, INC. | $29.81 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.92 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.67 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.46 | 2024 | Veozah |
| Pfizer INC. | $15.33 | 2024 | |
| Glaxosmithkline, LLC. | $15.21 | 2025 | Shingrix, Arexvy |
| Incyte Corporation | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Celeiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.